GINGER MCDANIEL: Open Payments
NPI 1477889590 · BIRMINGHAM, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$9,423 in 108 payments from 16 companies in 2025. Trend: 2023 $6,027 · 2024 $8,022 · 2025 $9,423
Speaker / faculty: $6,865Food & beverage: $2,106Travel & lodging: $354Education: $99
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 22 | $5,777 |
| Phathom Pharmaceuticals, Inc. | 6 | $1,887 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 17 | $315 |
| PFIZER INC. | 16 | $249 |
| Janssen Biotech, Inc. | 7 | $224 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $221 |
| Ardelyx, Inc. | 9 | $182 |
| Madrigal Pharmaceuticals | 9 | $177 |
| Celltrion USA Inc. | 5 | $108 |
| Gilead Sciences, Inc. | 1 | $80 |
Products named: LINZESS, VOQUEZNA, XIFAXAN, TREMFYA, ENTYVIO, XELJANZ, IBSRELA, REZDIFFRA.
Industry payments across AL — which companies pay providers there.
